Sign in
CSTL Stock Price, Chart, Stats & News
Castle Biosciences, Inc.
Save
Castle Biosciences, Inc. (CSTL) does not currently pay a dividend.
1.09B
Market cap
–
Current P/E
–
Forward P/E
CSTL chart
Fundamentals
Gross margin | 68.66% |
Operating margin | -12.44% |
Pretax margin | -8.57% |
Net margin | -7.02% |
Effective tax rate | 18.15% |
ROA | -4.18% |
ROE | -5.27% |
D/E | 0.08x |
Interest coverage ratio | -497.79x |
CSTL valuation
P/E | – |
P/S | 2.03x |
P/B | 1.47x |
P/CF | 10.73x |
P/FCF | 24.70x |
P/OCF | 10.73x |
PEG | 0.29x |
EV multiple | 59.34x |
About
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests.
Similar securities
Based on sector and market capitalization
Report issue